

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KELUN-BIOTECH
科伦博泰

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) dated November 24, 2023 in relation to the completion of the full circulation of certain domestic shares and unlisted foreign shares of the Company held by certain shareholders of the Company (the “**H Share Full Circulation**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that the Board has considered and approved the resolution on certain proposed amendments (the “**Proposed Amendments**”) to the articles of association of the Company (the “**Articles of Association**”) to reflect the share capital structure of the Company resulting from the completion of the H Share Full Circulation.

The Proposed Amendments to the Articles of Association are subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of special resolution(s). An extraordinary general meeting of the Company (the “**EGM**”) will be convened and held to put forward, among others, special resolution(s) for the Shareholders to consider and, if thought fit, approve the Proposed Amendments.

A circular containing, among others, further information on the Proposed Amendments and the notice of the EGM will be despatched to the Shareholders in due course.

By order of the Board

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

LIU Gexin

Chairman of the Board and Non-executive Director

Hong Kong, December 20, 2023

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.